

## Antifungal activity of silver nanoparticles on some of fungi

A. Nasrollahi<sup>1,\*</sup>, Kh. Pourshamsian<sup>2</sup>, P. Mansourkiaee<sup>3</sup>

<sup>1</sup>Department of biology, Faculty of science, Islamic azad university, Tonekabon branch, Tonekabon, Iran

<sup>2</sup>Department of chemistry, Faculty of science, Islamic azad university, Tonekabon branch, Tonekabon, Iran

<sup>3</sup>Basic science student, Member of young researchers club, Islamic azad university of Tonekabon, Iran

Received: 22 November 2010; Accepted: 12 January 2011

---

### Abstract

In this study, we investigated the antifungal effects of silver nanoparticles (Ag-Nps) on *Candida albicans* (ATCC 5027), *Saccharomyces cerevisiae* (ATCC 5027). Investigating method by using Minimum Inhibitory Concentration (MIC) technique, some of drugs including Amphotericin B, Fluconazole and synthesized Ag-Nps have been obtained on the fungi and the changes on membrane reactions of yeasts have been elucidated by Scanning Electron Microscopy (SEM). The present study indicates Ag-Nps has considerable antifungal activity comparison with other antifungal drugs, so deserving further investigation for clinical applications.

**Keywords:** *Silvernanoparticles (Ag-Nps), Antifungal activity, Minimum Inhibitory Concentration (MIC).*

---

### 1. Introduction

Nowadays fungal infections resulted from opportunistic fungi have been common especially in people talented in being affected by special conditions like immune weakness , pregnancy and diseases like HIV and the candidates of affection to theses infections. Antifungal drug therapy is no exception; resistance too many of the antifungal agents now in use has emerged. Although antifungal drug resistance does not seem to be as much of a problem as resistance to antibacterial agents in bacteria, one long-term concern is that the number of fundamentally different types of antifungal agents that are available for treatment remains extremely limited. This is because fungi are eukaryotic organisms with a structure and metabolism that are similar to those of eukaryotic hosts. Therefore, there is an inevitable and urgent medical need for antibiotics with novel antimicrobial mechanisms [1, 2].

---

\* Corresponding author: Ayat Nasrollahi

Department of Biology, Faculty of science, Islamic

Azad University, Tonekabon Branch, Iran.

Tel +98 911 375 3429, Fax +98 1924274409

Email [Ayat51@yahoo.co.in](mailto:Ayat51@yahoo.co.in)

In particular, because of the recent advances in research on metal nanoparticles, Ag-Nps have received special attention as a possible antimicrobial agent [1, 3-7, 16]. It has been known that silver and its compounds have strong inhibitory and bactericidal effects as well as a broad spectrum of antimicrobial activities for bacteria, fungi, and virus since ancient times [1, 7-8]. Compared with other metals, silver exhibits higher toxicity to microorganisms while it exhibits lower toxicity to mammalian cells [9]. Lately, the recent advances in researches on metal nanoparticles appear to revive the use of Ag-Nps for antimicrobial applications. It has been shown that Ag-Nps prepared with a variety of synthetic methods have effective antimicrobial activity [7-13]. Hence, Ag-Nps have been applied to a wide range of healthcare products, such as burn dressings, scaffold, water purification systems, and medical devices [14, 15]. The toxic effects of silver on bacteria have been investigated for more than 60 years [16]. And the acting mechanism of silver has been known in some extent [17]. Therefore, the preparation of uniform nanosized silver particles with specific requirements in terms of size, shape, and physical and chemical properties is of great interest in the formulation of new pharmaceutical products [18, 19].

## **2. Materials and methods**

### **2.1. Materials**

Amphotericin B powder, Fluconazole have been provided by sigma & Serva Company, dimethyl sulfoxide (DMSO) solution from Merck Company has been a transformer in all experiments, physiological serum, synthesized Ag-Nps was prepared using chemical reduction method.

### **2.2. Synthesis of Ag-Nps**

Ag-Nps were synthesized by reduction of silver nitrate in the presence of PVP. The procedure is briefly described as follows: Firstly, 5 ml NaBH<sub>4</sub> was refluxed in a three-necked round-bottom flask at 80 °C for 2h, then 5 ml NaBH<sub>4</sub> solution of 0.02 M silver nitrate and 5 ml NaBH<sub>4</sub> solution of 0.05mM PVP were simultaneously injected dropwise. When the first drops of silver nitrate and PVP/NaBH<sub>4</sub> solutions were added, the mixture turned yellow immediately. Continuing the injection, the solution became opaque gradually. By finishing the injection, the solution turned turbid with a grey color in about 15 min indicating the appearance of Ag-NPs. The reaction was continued at 80 °C for 24 h. After finishing the reaction and removal of the supernatant, a pink precipitate remained.

The Powder X-ray diffraction (XRD) pattern was recorded on a Seisert Argon 3003 PTC using nickel-filtered XD-3a Cu K radiations (D 1:5418 Å). Absorbance mode was recorded on a Hitachi spectrophotometer model U-2101 PC. The solution form of the sample was prepared by suspending a small amount of powder in ethanol. TEM was performed on a Philips EM208 and microscope operated at 100 kV. Sample was prepared by dispersing the powder in ethanol. Imaging was enabled by depositing a few drops of suspension on a carbon coated 400 mesh Cu grid. The solvent was allowed to evaporate before imaging [12].

### **2.3. Mechanism of Ag-Nps**

Ag-Nps attach to cell membrane and penetrate in the fungi then produce a site with little molecular weight in center of fungi, and then Ag-Nps attach to respiratory sequence and finally cell

division stop lead to cell death, Ag-Nps release silver ion in fungal cell which increase antifungal function as result [13].

#### **2.4. Microorganisms and culture conditions**

*Candida albicans* (ATCC 5027), *Saccharomyces cerevisiae* (ATCC 5027) have been provided from Iran researching organization collection and in all steps of experiment, we culture SCC (sabouraud dextrose agar containing Chloramphenicol and cycloheximide), SDB (sabouraud dextrose broth) to have new yeasts.

#### **2.5. Determination of antifungal susceptibility**

Fungal cells in MIC inoculated SCC related to these organisms have been determined by a double attenuating method, of experimental components that were done due to the standards of national association of laboratory and micro dilution method. Various concentrations of Ag-Nps and Fluconazole have been provided (highest concentration has been 256 mg/ml and the least one is 0.25 mg/ml) and different concentrations of Amphotericin B have been provided (highest concentration has been 32 mg/ml and the least one is 3.25 mg/ml). After 48 hour of incubation in 37 °C, the least concentrations of the studied components have been determined, that stopped the process of growth for 50 to 90%. The process of growth is controlled and evaluated through the culture. The used culture is SCC.

#### **2.6. Scanning Electron Microscopy (SEM)**

The morphological changes of *Candida albicans*, *Saccharomyces cerevisiae* by Ag-NPs were observed with a scanning electron microscope (SEM). Strains were prepared by cutting the agar, fixed for a minimum of 3 h in 2.5% (v/v) glutaraldehyde (100mM phosphate buffer solution, pH 7.2), and then fixed in 1% (w/v) osmium tetra oxide for 1 h. The agar blocks were dehydrated through a graded series of ethanol (30, 50, 60, 70, 80, 90, 95, and 100%; each level was applied twice for 15 min each time) and ethanol: isoamyl acetate (3:1, 1:1, 1:3, and 100% isoamyl acetate twice for 30 min). The agar blocks on grid were dried with a critical-point drier using liquid CO<sub>2</sub> and coated with gold-coater for 5 min. The coated samples were observed under JSM-5600LV with accelerating voltage of 10 kV.

#### **2.7. Measurement of Minimum Inhibitory Concentration (MIC)**

Different concentration of Ag-NPs (0, 5, 10, 50, 100 ppm) was added in LB medium. Each fungal culture (*Candida albicans*, *Saccharomyces cerevisiae*) was incubated at 35°C. To establish the antimicrobial activity of Ag-NPs on the fungal growth, the MIC of Ag-NPs for *Candida albicans*, *Saccharomyces cerevisiae* was determined by optical density of the fungal culture solution containing different concentration of each Ag-NP after 24 h.

### **3. Results**


The antifungal activity of Ag-NPs against *Candida albicans*, *Saccharomyces cerevisiae* as models for fungi was investigated and Ag-NPs has been used as a comparable antifungal drug by antifungal drugs like Amphotericin B, Fluconazole. Ag-NPs exhibited a potent antifungal activity against fungal strains tested. To investigate growth inhibition effect of Ag-NPs against *Candida albicans*, *Saccharomyces cerevisiae*, we measured the MIC.MIC<sub>50</sub> of Amphotericin B and

Fluconazole, Ag-NPs on *Candida albicans* were 1mg/ml, 8mg/ml, 0.5 mg/ml respectively, MIC90 of Amphotericin B and Fluconazole, Ag-NPs on *Candida albicans* were 4mg/ml, 16mg/ml, 2 mg/ml Respectively (Table1). MIC50 of Amphotericin B and Fluconazole, Ag-NPs on *Saccharomyces cerevisiae* were 16mg/ml, 64mg/ml, 4 mg/ml respectively, MIC90 of Amphotericin B and Fluconazole, Ag-NPs on *Saccharomyces cerevisiae* were 32 mg/ml, 256mg/ml, 32 mg/ml Respectively (Table 1).

**Table.1.** MIC50 and MIC90 of Amphotericin B, Fluconazole, Ag-NPs on *Candida albicans* and *Saccharomyces cerevisiae*

Sample:	<i>Candida albicans</i>			<i>Saccharomyces cerevisiae</i>		
	MIC50 mg/ml	MIC90mg/ml	RANGE	MIC50 mg/ml	MIC90mg/ml	RANGE
AmphotericinB	1	4	0.01325 - 32	16	32	-
Fluconazole	8	16	0.25 - 64	64	256	-
Ag-NPs	0.5	2	-	4	32	-


(In) According to this result, we understood the effect of Amphotericin B is more than to Fluconazole, and Ag-NPs have more potent effect than to Amphotericin B and Fluconazole, on *Saccharomyces cerevisiae*, *Candida albicans*. This fact is true about both MIC<sub>50</sub> and MIC<sub>90</sub>, because when the number of MIC is low, the drugs have more lethal characteristics. So we can substitute the chemical drugs with Ag-NPs to treat disease. This comparison is shown in SEM graphs. When we used *Saccharomyces cerevisiae* as model for test we observed it such other healthy yeast with spherical shape and smooth cell wall and completely cell membrane because we didn't use any drug (Figure 1.A). But when we used 4 mg/ml (MIC<sub>90</sub>) concentration of Ag-NPs we observed membrane damage and some pits that have been created cause inter cellular components leakage and finally cell death (Figure 1.B). Also we influenced fungi cell by 32 mg/ml (MIC<sub>50</sub>) concentration of Ag-NPs, we observed the same result as above result (Figure 1.C).



**Fig.1.** Scanning electron microscopy images of *Saccharomyces cerevisiae*. Normal cells (A) and cells influence by 4 mg/ml (MIC<sub>90</sub>) concentration of Ag-NPs (B) and cells influence by 32 mg/ml (MIC<sub>50</sub>) concentration of Ag-NPs (C) (10 ppm).

Finally using *Candida albicans* as our second fungi model and not using any drug, we observed healthy fungi cell under SEM (Figure 2.A) but when we used 0.5 mg/ml (MIC<sub>50</sub>) concentration of Ag-NPs (fig.2.B) and cells influenced by 2 mg/ml (MIC<sub>90</sub>) Concentration of Ag-NPs (Figure 2.A), we observed destroy fungal cell with pore in their cell membrane. The result of Scanning Electron Microscopy (SEM) on two model yeast (*Saccharomyces cerevisiae*, *Candida*

albicans) show reciprocal correlation between Ag-NPs and membrane structure, cause damage and then death of fungal cell. SEM has been used for evaluating Ag-NPs capability in destroying surface membrane structure of the fungus.



**Fig.2.** Scanning electron microscopy images of *Candida albicans*. Normal cells (A) and cells influence by 0.5mg/ml (MIC50) concentration of Ag-NPs (B) and cells influence by 2 mg/ml (MIC90) concentration of Ag-NPs (C) (10 ppm).

These results indicated that Ag-NPs have remarkable potential as an antifungal agent in treating fungal infectious diseases.

#### 4. Discussion

In this study, the antifungal activity of Ag-NPs toward *C. albicans* and *Saccharomyces cerevisiae* as models for fungi was investigated. Ag-NPs exhibited a potent antifungal activity against fungal strains tested, similar to the antifungal activity in the MIC values of Amphotericin B and Fluconazole, which were used as a positive control. These results indicated that Ag-NPs have remarkable potential as an antifungal agent in treating fungal infectious diseases. To provide information on the mode of action of Ag-NPs, its ability to dissipate the membrane potential of *C. albicans* and *Saccharomyces cerevisiae* were investigated (Figure 2).

Many antimicrobial agents are limited in clinical applications, because of their much complications, for example Amphotericin B has bad affect on kidneys and kidney renal failure, fever, tremble, nausea, diarrhea have seen after using these drugs. The Azoles family like Fluconazole, cause liver toxicity and stopping in testosterone synthesis. So that requiring new drugs with less complications components in hosts is considered for knowing Ag-NPs function, its ability in destroying yeasts potential and membrane function have been investigated. Fungal cells by having ergosterol in the membrane and by making various gradients between cytoplasmic membranes can keep their membrane potential ability. As a result of using antifungal drugs and Ag-NPs, these gradients and membrane conformity have been destroyed and it causes cell death. Additionally, SEM analysis confirms the interaction between Ag-NPs and the membrane structure of *C. albicans* and *Saccharomyces cerevisiae* cells, during Ag-NPs exposure, show significant changes to their membranes, which are recognized by the formation of “pits” on their surfaces, and finally, result in the formation of pores and cell death (Figure 2). Endo *et al.* have reported that the inhibition of bud growth correlates with membrane damage [9]. This report suggests that Ag-NPs inhibit the normal budding process, probably through the destruction of membrane integrity. Finally, Ag-NPs exhibited potent antifungal effects on fungi tested, probably through destruction of membrane integrity; therefore, it was concluded that Ag-NPs has considerable antifungal activity, deserving further investigation for clinical applications.

## Acknowledgments

The financial and encouragement support provided by the Research vice Presidency of Tonekabon Branch, Islamic Azad University and Executive Director of Iran-Nanotechnology Organization (Govt. of Iran).

## References

- [1] Silver ,S. (2003), Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. *FEMS. Microbiol. Rev*, 27,341–353.
- [2] Klasen ,H.J. (2000), A historical review of the use of silver in the treatment of burns. *II. Renewed interest for silver. Burns*, 26,131–138.
- [3] Baker, C., Pradhan, A., Pakstis, L., Pochan, D. J., Shah, S. I. (2005), Synthesis and antibacterial properties of silver nanoparticles. *J. Nanosci. Nanotechnol*, 5, 244-249.
- [4] Lee, B.U., Yun, S.H., Ji, J.-H., Bae, G.-N. (2008), Inactivation of *S. epidermidis*, *B.subtilis*, and *E. coli* bacteria bioaerosols deposited on a filter utilizing airborne silver nanoparticles. *J. Microbiol. Biotechnol*,18,176-182.
- [5] Melaiye, A., Sun, Z., Hindi, K., Milsted, A., Ely, D., Reneker, D.H., Tessier, C.A., Youngs, W.J. (2005), Silver(I)-imidazole cyclophane gem-diol complexes encapsulated by electrospun tectophilic nanofibers: Formation of nanosilver particles and antimicrobial activity. *J. Am.Chem. Soc*, 127, 2285-2291.
- [6] Sondi, I., Salopek-Sondi, B. (2004), Silver nanoparticles as antimicrobial agent: A case study on *E. coli* as a model for Gram-negative bacteria. *J. Colloid Interface Sci*, 275, 177-182.
- [7] Lok, C.N., Ho, C.M., Chen, R., He, Q.Y., Yu, W.Y., Sun, H., Tam, P.K., Chiu, J.F., Chen, C.M. (2006), Proteomic analysis of the mode of antibacterial action of silver nanoparticles. *J. Proteome. Res* , 5,916–924.
- [8] Cho, K.H., Park, J.E., Osaka, T., Park, S.G.(2005), The study of antimicrobial activity and preservative effects of nanosilver ingredient. *Electrochim Acta*, 51,956–960.
- [9] Zhao, G.J., Stevens, S.E. (1998), Multiple parameters for the comprehensive evaluation of the susceptibility of *Escherichia coli* to the silver ion. *Biometals*,11,27–32.
- [10] Aymonier, C., Schlotterbeck, U., Antonietti, L., Zacharias, P., Thomann, R., Tiller, J.C., Mecking, S.(2002), Hybrids of silver nanoparticles with amphiphilic hyperbranched macromolecules exhibiting antimicrobial properties. *Chem Commun*, 24,3018–3019.
- [11] Kim, J.Y., Lee, C., Cho, M., Yoon, J. (2008), Enhanced inactivation of *E. coli* and MS-2 phage by silver ions combined with UV-A and visible light irradiation. *Water Res*, 42,356–362.
- [12] Lee, D.G., Kim, H.K., Kim, S.A., Park, Y., Park, S-C., Jang, S-H. (2003), Fungicidal effect of indolicidin and its interaction with phospholipids membranes. *Biochem Biophys. Res Commun*, 305,305–310.
- [13] Alt,V., Bechert, T., Steinrucke, P., Wagener, M., Seidel, P., Dingeldein, E., Domann, E., Schnettler, R.(2004), an in vitro assessment of the antibacterial properties and cytotoxicity of nanoparticulate silver bone cement. *Biomaterials*, 25,4383–4391.

- [14] Thomas, V., Yallapu, M.M., Sreedhar, B., Bajpai, S.K. (2007), A versatile strategy to fabricate hydrogel–silver nanocomposites and investigation of their antimicrobial activity. *J Colloid Interface Sci*, 315,389–395.
- [15] Kim, S., Kim, H.J. (2006), Anti-bacterial performance of colloidal silver-treated laminated wood flooring. *Int Biodeterioration Biodegradation*, 57,155–162.
- [16] Franke, S., Grass, G., Nies, D.H. (2001), the product of the ybdE gene of the Escherichia coli chromosome is involved in detoxification of silver ions. *Microbiol*, 147,965–972.
- [17] Rai, M., Yadav, A., Gade, A. (2009), Silver nanoparticles as a new generation of microbials. *Biotechnol. Adv*, 27,76–83.
- [18] Merisko-Liversidge, E., Liversidge, G.G., Cooper, E.R. (2003), Nanosizing: a formulation approach for poorly-water-soluble compounds. *Eur. J. Pharm Sci*, 18,113–120.
- [19] Brigger, I., Dubernet, C., Couvreur, P. (2002), Nanoparticles in cancer therapy and diagnosis. *Adv Drug Deliv Rev*, 54,631–651.